Immuneering Corp
IMRX· Nasdaq
IMRXImmuneering Corp
Filed Sep 9, 2021 · 10-Q · 71 days after period end · 0001558370-21-012336
| Metric | Q2 2021 | Q2 2020 |
|---|---|---|
| Revenue | $660.04K | $480.84K |
| Net Income | -$7.99M | -$3.60M |
| EPS Diluted | -$1.61 | -$0.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immuneering Corp · CIK 1790340 · Engraved from SEC EDGAR
ended Jun 30, 2021 · filed Sep 9, 2021 · 71 d after period end
